279 related articles for article (PubMed ID: 29405820)
1. The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells.
Booth L; Roberts JL; Samuel P; Avogadri-Connors F; Cutler RE; Lalani AS; Poklepovic A; Dent P
Cancer Biol Ther; 2018 Jun; 19(6):525-533. PubMed ID: 29405820
[TBL] [Abstract][Full Text] [Related]
2. The irreversible ERBB1/2/4 inhibitor neratinib interacts with the BCL-2 inhibitor venetoclax to kill mammary cancer cells.
Booth L; Roberts JL; Avogadri-Connors F; Cutler RE; Lalani AS; Poklepovic A; Dent P
Cancer Biol Ther; 2018 Mar; 19(3):239-247. PubMed ID: 29333953
[TBL] [Abstract][Full Text] [Related]
3. Neratinib and entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, Gα
Booth L; Roberts JL; Sander C; Lalani AS; Kirkwood JM; Hancock JF; Poklepovic A; Dent P
Cancer Biol Ther; 2019; 20(5):700-710. PubMed ID: 30571927
[TBL] [Abstract][Full Text] [Related]
4. Valproate augments Niraparib killing of tumor cells.
Booth L; Roberts JL; Rais R; Poklepovic A; Dent P
Cancer Biol Ther; 2018; 19(9):797-808. PubMed ID: 29923797
[TBL] [Abstract][Full Text] [Related]
5. The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib.
Booth L; Roberts JL; Poklepovic A; Kirkwood J; Sander C; Avogadri-Connors F; Cutler RE; Lalani AS; Dent P
Cancer Biol Ther; 2018 Feb; 19(2):132-137. PubMed ID: 29219657
[TBL] [Abstract][Full Text] [Related]
6. Palbociclib augments Neratinib killing of tumor cells that is further enhanced by HDAC inhibition.
Booth L; Roberts JL; Rais R; Cutler RE; Diala I; Lalani AS; Poklepovic A; Dent P
Cancer Biol Ther; 2019; 20(2):157-168. PubMed ID: 30183517
[TBL] [Abstract][Full Text] [Related]
7. The CHK1 inhibitor SRA737 synergizes with PARP1 inhibitors to kill carcinoma cells.
Booth L; Roberts J; Poklepovic A; Dent P
Cancer Biol Ther; 2018; 19(9):786-796. PubMed ID: 30024813
[TBL] [Abstract][Full Text] [Related]
8. Neratinib kills B-RAF V600E melanoma via ROS-dependent autophagosome formation and death receptor signaling.
Dent P; Booth L; Poklepovic A; Kirkwood JM
Pigment Cell Melanoma Res; 2022 Jan; 35(1):66-77. PubMed ID: 34482636
[TBL] [Abstract][Full Text] [Related]
9. Neratinib inhibits Hippo/YAP signaling, reduces mutant K-RAS expression, and kills pancreatic and blood cancer cells.
Dent P; Booth L; Roberts JL; Liu J; Poklepovic A; Lalani AS; Tuveson D; Martinez J; Hancock JF
Oncogene; 2019 Jul; 38(30):5890-5904. PubMed ID: 31253872
[TBL] [Abstract][Full Text] [Related]
10. Neratinib augments the lethality of [regorafenib + sildenafil].
Booth L; Roberts JL; Rais R; Cutler RE; Diala I; Lalani AS; Hancock JF; Poklepovic A; Dent P
J Cell Physiol; 2019 Apr; 234(4):4874-4887. PubMed ID: 30203445
[TBL] [Abstract][Full Text] [Related]
11. The Lethality of [Pazopanib + HDAC Inhibitors] Is Enhanced by Neratinib.
Booth L; Roberts JL; Poklepovic A; Dent P
Front Oncol; 2019; 9():650. PubMed ID: 31380285
[TBL] [Abstract][Full Text] [Related]
12. The multi-kinase inhibitor lenvatinib interacts with the HDAC inhibitor entinostat to kill liver cancer cells.
Roberts JL; Poklepovic A; Booth L; Dent P
Cell Signal; 2020 Jun; 70():109573. PubMed ID: 32087304
[TBL] [Abstract][Full Text] [Related]
13. Neratinib decreases pro-survival responses of [sorafenib + vorinostat] in pancreatic cancer.
Booth L; Poklepovic A; Dent P
Biochem Pharmacol; 2020 Aug; 178():114067. PubMed ID: 32504550
[TBL] [Abstract][Full Text] [Related]
14. HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody
Booth L; Roberts JL; Poklepovic A; Avogadri-Connors F; Cutler RE; Lalani AS; Dent P
Oncotarget; 2017 Oct; 8(52):90262-90277. PubMed ID: 29163826
[TBL] [Abstract][Full Text] [Related]
15. Niraparib: A Review in Ovarian Cancer.
Heo YA; Duggan ST
Target Oncol; 2018 Aug; 13(4):533-539. PubMed ID: 30073633
[TBL] [Abstract][Full Text] [Related]
16. Niraparib in the treatment of previously treated advanced ovarian, fallopian tube or primary peritoneal cancer.
Rimel BJ; Dockery L; Randall LM; Moore K
Future Oncol; 2020 Nov; 16(33):2701-2711. PubMed ID: 32880196
[TBL] [Abstract][Full Text] [Related]
17. Rationally Repurposing Ruxolitinib (Jakafi (®)) as a Solid Tumor Therapeutic.
Tavallai M; Booth L; Roberts JL; Poklepovic A; Dent P
Front Oncol; 2016; 6():142. PubMed ID: 27379204
[TBL] [Abstract][Full Text] [Related]
18. Combination of Niraparib, Cisplatin and Twist Knockdown in Cisplatin-Resistant Ovarian Cancer Cells Potentially Enhances Synthetic Lethality through ER-Stress Mediated Mitochondrial Apoptosis Pathway.
Bahar E; Kim JY; Kim DC; Kim HS; Yoon H
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920140
[TBL] [Abstract][Full Text] [Related]
19. Fingolimod augments Pemetrexed killing of non-small cell lung cancer and overcomes resistance to ERBB inhibition.
Booth L; Roberts JL; Spiegel S; Poklepovic A; Dent P
Cancer Biol Ther; 2019; 20(5):597-607. PubMed ID: 30388910
[TBL] [Abstract][Full Text] [Related]
20. The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo.
Booth L; Roberts JL; Sander C; Lee J; Kirkwood JM; Poklepovic A; Dent P
Oncotarget; 2017 Mar; 8(10):16367-16386. PubMed ID: 28146421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
